印度旁遮普邦Sangrur和Mansa癌症登记处前列腺癌症总生存率。

IF 1.3 Q3 UROLOGY & NEPHROLOGY
Indian Journal of Urology Pub Date : 2023-04-01 Epub Date: 2023-03-31 DOI:10.4103/iju.iju_38_23
Atul Madhukar Budukh, Jarnail S Thakur, Tapas Kumar Dora, Prithviraj R Kadam, Sonali S Bagal, Kamalesh Kumar Patel, Alok K Goel, Sankalp M Sancheti, Ashish R Gulia, Pankaj P Chaturvedi, Rajesh P Dikshit, Rajendra A Badwe
{"title":"印度旁遮普邦Sangrur和Mansa癌症登记处前列腺癌症总生存率。","authors":"Atul Madhukar Budukh,&nbsp;Jarnail S Thakur,&nbsp;Tapas Kumar Dora,&nbsp;Prithviraj R Kadam,&nbsp;Sonali S Bagal,&nbsp;Kamalesh Kumar Patel,&nbsp;Alok K Goel,&nbsp;Sankalp M Sancheti,&nbsp;Ashish R Gulia,&nbsp;Pankaj P Chaturvedi,&nbsp;Rajesh P Dikshit,&nbsp;Rajendra A Badwe","doi":"10.4103/iju.iju_38_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India.</p><p><strong>Methods: </strong>In the year 2013-2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method.</p><p><strong>Results: </strong>Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10-0.27]).</p><p><strong>Conclusion: </strong>To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.</p>","PeriodicalId":47352,"journal":{"name":"Indian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/8f/IJU-39-148.PMC10249534.pdf","citationCount":"4","resultStr":"{\"title\":\"Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India.\",\"authors\":\"Atul Madhukar Budukh,&nbsp;Jarnail S Thakur,&nbsp;Tapas Kumar Dora,&nbsp;Prithviraj R Kadam,&nbsp;Sonali S Bagal,&nbsp;Kamalesh Kumar Patel,&nbsp;Alok K Goel,&nbsp;Sankalp M Sancheti,&nbsp;Ashish R Gulia,&nbsp;Pankaj P Chaturvedi,&nbsp;Rajesh P Dikshit,&nbsp;Rajendra A Badwe\",\"doi\":\"10.4103/iju.iju_38_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India.</p><p><strong>Methods: </strong>In the year 2013-2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method.</p><p><strong>Results: </strong>Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10-0.27]).</p><p><strong>Conclusion: </strong>To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.</p>\",\"PeriodicalId\":47352,\"journal\":{\"name\":\"Indian Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/55/8f/IJU-39-148.PMC10249534.pdf\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Urology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/iju.iju_38_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/3/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/iju.iju_38_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 4

摘要

简介:印度缺乏基于人口的前列腺癌症生存数据。我们评估了来自印度旁遮普邦Sangrur和Mansa癌症登记处的前列腺癌症患者的基于人群的总体生存率。方法:2013-2016年,这两个登记处共登记了171例癌症病例。基于这些登记,以诊断日期为开始日期进行生存分析,最后一次随访日期为2021年12月31日或死亡日期。使用STATA软件计算生存率。使用Pohar Perme方法计算相对生存率。结果:所有登记病例均能进行随访。171例中,41例(24%)存活,130例(76.0%)死亡。在规定的治疗中,106例(62.7%)完成了治疗,63例(37.3%)未完成治疗。总体而言,5年年龄标准化前列腺癌症的相对生存率为30.3%。完成治疗的患者的5年相对生存率(45.5%)是未完成治疗的(5.8%)的7.8倍。两组之间的差异具有统计学意义(危险比0.16,95%置信区间[0.10-0.27])。结论:为了提高生存率,我们需要提高社区和初级医生的意识,以便癌症患者能够尽早到达医院并得到有效治疗。癌症中心应该在医院开发这些系统,这样患者在完成治疗时就不会有障碍。我们发现,在这两个登记中,癌症前列腺患者的总体相对生存率较低。接受治疗的患者存活率明显较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India.

Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India.

Introduction: There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India.

Methods: In the year 2013-2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method.

Results: Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10-0.27]).

Conclusion: To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Indian Journal of Urology
Indian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
1.90
自引率
0.00%
发文量
62
审稿时长
33 weeks
期刊介绍: Indian Journal of Urology-IJU (ISSN 0970-1591) is official publication of the Urological Society of India. The journal is published Quarterly. Bibliographic listings: The journal is indexed with Abstracts on Hygiene and Communicable Diseases, CAB Abstracts, Caspur, DOAJ, EBSCO Publishing’s Electronic Databases, Excerpta Medica / EMBASE, Expanded Academic ASAP, Genamics JournalSeek, Global Health, Google Scholar, Health & Wellness Research Center, Health Reference Center Academic, Hinari, Index Copernicus, IndMed, OpenJGate, PubMed, Pubmed Central, Scimago Journal Ranking, SCOLOAR, SCOPUS, SIIC databases, SNEMB, Tropical Diseases Bulletin, Ulrich’s International Periodical Directory
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信